Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655219 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL12416491 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL3275528 | 0.86 | MGAM (0.48) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL16093587 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAGLAMAPK1 | |
| SCHEMBL17193769 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL2027803 | 0.83 | MGAM (0.46) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL22623634 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL12197531 | 0.81 | MGAM (0.45) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL15775618 | 0.81 | MGAM (0.45) | ALDH1A1LMNAMGAMGAASI | |
| Hydrochloric Acid SCHEMBL15775617 | 0.80 | MGAM (0.44) | ALDH1A1LMNAMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016998-A1 | HIGH-AFFINITY MATRIPTASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016998-A1 | HIGH-AFFINITY MATRIPTASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-8329916-B2 | Human protein tyrosine phosphatase inhibitors and method of use | AERPIO THERAPEUTICS INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | EyePoint Pharmaceuticals, Inc. | 2012-03-29 | — | — | US | disclosed |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-18 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | PTPRCAP, PPP5C, PTPRO | ALDH1A1 4348/4885LMNA 4502/4885MGAM 3040/4885 |
| US-20160016998-A1 | HIGH-AFFINITY MATRIPTASE INHIBITORS | MMP7, MATR3, TMPRSS15 | ALDH1A1 4072/4885LMNA 2335/4885MGAM 451/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | ALDH1A1 796/4885LMNA 1922/4885MGAM 2111/4885 |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | CTSA, SOST, CTSB | ALDH1A1 4434/4885LMNA 1974/4885MGAM 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.